Search Results - "Binas, I."

Clinical significance of RCAS1 and CD3 expression in non-small cell lung cancers in immunotherapy era by Tsoukalas, N.G., Aravantinou, E., Tsapakidis, K., Giaginis, C., Tolia, M., Binas, I., Baxevanos, P., Galanopoulos, M., Kiakou, M., Kostakis, I., Nikolaou, C., Litos, I., Liontos, M., Tsiambas, E., Gioulbasanis, I., Sfiniadakis, I., Karameris, A., Kyrgias, G., Theocharis, S., Tsiatas, M.

Get full text

978 PLATELET FUNCTION IN PATIENTS WITH EARLY PRIMARY BILIARY CIRRHOSIS ESTIMATED BY ROTEM THROMBOELASTOGRAPHY AND FLOW CYTOMETRY. COMPARISON WITH HEALTHY CONTROLS by Binas, I, Vlachogiannakos, J, Kotsi, P, Anastasopoulou, I, Vafiadi-Zoumbouli, I, Ladas, S.D

Get full text

Mass-dependence of self-diffusion coefficients in disparate-mass binary fluid mixtures by I. Binas, I. Mryglod

“…Self-diffusion coefficients of a binary fluid mixture with components differing only in their particle masses are studied, in particular the case when mass…”
Get full text

Real-world data on the safety and efficacy of trastuzumab deruxtecan and sacituzumab govitecan in patients with advanced breast cancer: the experience of the Hellenic Cooperative Oncology Group by Fountzilas, E., Lalla, T., Karakatsoulis, G., Papazisis, K., Exarchos, K., Koumarianou, A., Nikolaidi, A., Binas, I., Mauri, D., Karageorgopoulou, S., Razis, E., Christopoulou, A., Boutis, A., Douganiotis, G., Zagouri, F., Stamatopoulou, S., Spathas, N., Tryfonopoulos, D., Psyrri, A., Koutras, A.

Get full text

2122P Clinical significance of oncology patients’ nutritional status assessment by Kostaridis, E.P., Michas, A., Gkikas, K., Arvanitou, E., Pouliakis, A., Tsitsimpis, A., Chantzipavlou, M., Xantzaridis, P., Panagou, E., Kagaras, X., Binas, I., Gkiaouraki, M., Stamatogianni, E., Ballasis, K., Christofyllakis, C., Tsoukalas, N.G.

Get full text

1181P Real-world data on neuroendocrine neoplasms (NENs): Preliminary results of an observational study by the Hellenic Society of Medical Oncology (HeSMO) by Tsoukalas, N.G., Koumarianou, A., Syrigos, K., Angelaki, S., Ziras, N., Demiri, M., Kampoli, K., Ntavatzikos, A., Binas, I., Stergiou, E., Evangelou, G., Georgiadou, M., Papafili, A., Tzouda, V., Karadimou, A., Kamposioras, K.V., Athanasiadis, A., Souglakos, I., Georgoulias, V., Boukovinas, I.

Get full text

Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting by Fountzilas, E., Koliou, G.-A., Rapti, V., Nikolakopoulos, A., Christopoulou, A., Moirogiorgou, E., Binas, I., Aravantinos, G., Kostadima, L., Nikolaidi, A., Karteri, S., Zagouri, F., Saridaki, Z., Molfeta, A., Oikonomopoulou, P., Res, E., Tryfonopoulos, D., Koumakis, G., Fountzilas, G., Razis, E.

Get full text

334PClinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting by Fountzilas, E, Koliou, G -A, Rapti, V, Nikolakopoulos, A, Christopoulou, A, Moirogiorgou, E, Binas, I, Aravantinos, G, Kostadima, L, Nikolaidi, A, Karteri, S, Zagouri, F, Saridaki, Z, Molfeta, A, Oikonomopoulou, P, Res, E, Tryfonopoulos, D, Koumakis, G, Fountzilas, G, Razis, E

“…Abstract Background Clinical trials evaluating treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with aromatase inhibitors (AI) or…”
Get full text

334P - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting by Fountzilas, E., Koliou, G.-A., Rapti, V., Nikolakopoulos, A., Christopoulou, A., Moirogiorgou, E., Binas, I., Aravantinos, G., Kostadima, L., Nikolaidi, A., Karteri, S., Zagouri, F., Saridaki, Z., Molfeta, A., Oikonomopoulou, P., Res, E., Tryfonopoulos, D., Koumakis, G., Fountzilas, G., Razis, E.

“…Clinical trials evaluating treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with aromatase inhibitors (AI) or fulvestrant have…”
Get full text

84P Actual 5-year survival of dose-dense sequential adjuvant chemotherapy in early breast cancer (BC) patients treated in the post-trastuzumab era: A pooled analysis of 3 clinical trials by Aravantinou Fatorou, E., Koliou, G-A., Zagouri, F., Kostadima, L., Gogas, H., Pectasides, D., Binas, I., Koutras, A., Aravantinos, G., Psyrri, A., Lazaridis, G.L., Bafaloukos, D., Saloustros, E., Karanikiotis, C., Bombolaki, I.B., Razis, E., Koumarianou, A., Papakostas, P., Kosmidis, P., Fountzilas, G.

Get full text

P178 Contemporary management of patients in Greece with advanced/metastatic renal-cell carcinoma: real-world treatment patterns and patient profiling by Zakopoulou, R., Papatheodoridi, A., Nikolakopoulos, A., Kyriazoglou, A., Moutafi, M., Gavrielatou, N., Mpoulouta, A., Papanota, A., Kaparelou, M., Pispirigkou, M., Binas, I., Bozionelou, V., Emmanouil, G., Dimitriadis, I., Christodoulou, C., Mavroudis, D., Koutras, A., Zagouri, F., Bamias, A.

Get full text

176PClinical significance of RCAS1 and CD3 expression in non-small cell lung cancers in immunotherapy era by Tsoukalas, N G, Aravantinou, E, Tsapakidis, K, Giaginis, C, Tolia, M, Binas, I, Baxevanos, P, Galanopoulos, M, Kiakou, M, Tsiatas, M, Kostakis, I, Nikolaou, C, Litos, I, Liontos, M, Tsiambas, E, Gioulbasanis, I, Sfiniadakis, I, Karameris, A, Kyrgias, G, Theocharis, S

Get full text

Characteristics and treatment patterns of patients with advanced/metastatic renal-cell carcinoma treated with first line checkpoint inhibitors. A Real-world experience by Zakopoulou, R., Koutsoukos, K., Angelidou, A., Kyriazoglou, A., Moutafi, M., Andrikopoulou, A., Gavrielatou, N., Mpoulouta, A., Papatheodoridi, A., Kapodistrias, N., Binas, I., Emmanouil, G., Dimitriadis, I., Christodoulou, C., Mavroudis, D., Koutras, A., Zagouri, F., Bamias, A.

Get full text

P154 - Characteristics and treatment patterns of patients with advanced/metastatic renal-cell carcinoma treated with first line checkpoint inhibitors. A Real-world experience by Zakopoulou, R., Koutsoukos, K., Angelidou, A., Kyriazoglou, A., Moutafi, M., Andrikopoulou, A., Gavrielatou, N., Mpoulouta, A., Papatheodoridi, A., Kapodistrias, N., Binas, I., Emmanouil, G., Dimitriadis, I., Christodoulou, C., Mavroudis, D., Koutras, A., Zagouri, F., Bamias, A.

Get full text

Primary Amelanotic Anorectal Melanoma with Upper Gastrointestinal and Brain Metastases by Klimis, A., Doulgeroglou, V., Phytrakis, N., Binas, I.

“…Background The anorectum is a rare anatomic location for primary melanoma. In many cases the disease is undetected or is misdiagnosed as a benign polyp or…”
Get full text

Mini Review : Embryo-derived stem cells -a system is emerging by B. Binas

Get full text

Embryo-derived stem cells -a system is emerging by Binas, B

“…In mammals, major progress has recently been made with the dissection of early embryonic cell specification, the isolation of stem cells from early embryos,…”
Get full text